A deep-dive into Nigeria's in-vitro diagnostics and point-of-care testing market — disease burden, market sizing, consumer behaviour, supply gaps, and the 5-year trend outlook for Lagos and Abuja.
Nigeria's triple burden of infectious disease, maternal mortality, and rising NCDs makes it uniquely dependent on point-of-care diagnostics — yet diagnostic penetration remains critically low.
AyoHealth's market divides cleanly across three B2B customer types and two B2C consumer segments — each with distinct needs, buying behaviour, and value levers.
~120,000 nationwide; >30,000 in Lagos alone. Largest private health touchpoint. Chronically understocked on RDTs. Key first adopter channel for AyoPharm chatbot.
~6,500 registered in Lagos + Abuja. Growing interest in diagnostic revenue as drug margins compress. Preferred channel for bundled kit sales and AyoIntel SaaS subscriptions.
>5,000 facilities in Lagos State; ~1,500 in FCT. High-value institutional kit purchasers. Main buyers of Maternal, Neonatal, and NCD Monitoring kits. AyoData primary data source.
Validated pain points from published market surveys, WHO assessments, and Nigerian health tech operator interviews — each representing a direct monetization opportunity.
No pharmacist has real-time visibility into when stock will run out. Orders are placed reactively after stockout — causing treatment delays and lost revenue.
Only 22% of private pharmacies stock malaria RDTs because patient demand is low. Patients and pharmacists both treat "by feel." The diagnostic habit must be created.
Clinics source each test component separately from different vendors — wasting procurement time, creating inconsistencies, and increasing per-test cost.
Each facility diagnoses in isolation. There is no mechanism to detect cluster outbreaks, share LGA-level disease signals, or alert peer providers to emerging trends.
The majority of Lagos/Abuja households self-diagnose malaria from experience and buy ACTs without testing. Over 50% of fever cases treated as malaria are not malaria.
Nigeria has <4 doctors per 10,000 people. Urban Nigerians have no reliable way to triage symptoms outside business hours without visiting expensive private ERs.
The next five years will be shaped by structural shifts in Nigerian healthcare policy, technology adoption, and global supply chain realignment — all creating tailwinds for AyoHealth.
President Tinubu's executive order eliminates all import duties and VAT on rapid diagnostic kits and raw materials for 2 years. First-mover distributors lock in supply at dramatically lower COGS.
US funding withdrawal creates an RDT supply gap across West Africa. Codix Bio — now producing 147M kits/year — needs commercial distributors urgently. A rare first-mover advantage.
Nigeria's Pharmacy Council launched the Electronic Pharmacy Regulation Platform in April 2026, legitimising digital diagnostic distribution and creating a regulatory framework AyoHealth can anchor to.
HealthGrid, GabbiDoc, MamaBot, Solayo Africa, and HubPharm's Afiya are all proving that WhatsApp is Nigeria's primary healthcare AI interface. Pharmacist-facing tools are the underserved segment.
Codix Bio's goal is 90% domestic production by 2028. Local kit prices will fall further, expanding the addressable market into lower-income deciles and rural distribution networks.
Nigeria is the fastest-growing POC diagnostics country in Africa (Data Bridge Market Research, 2026) — driven by urbanisation, rising private health spend, and expanding smartphone penetration in Lagos and Abuja.